Aging and Venous Thromboembolism Influence the Pharmacodynamics of the Anti-Factor Xa and Anti-thrombin Activities of a Low Molecular Weight Heparin (Nadroparin)

P. Mismetti; S. Laporte-Simitsidis; C. Navarro; P. Sié; P. d’Azemar; J. Necciari; J. P. Duret; C. Gaud; H. Decousus; B. Boneu

doi:10.1055/s-0037-1615034

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 79(06): 1162-1165
DOI: 10.1055/s-0037-1615034

Rapid Communication

Schattauer GmbH

Aging and Venous Thromboembolism Influence the Pharmacodynamics of the Anti-Factor Xa and Anti-thrombin Activities of a Low Molecular Weight Heparin (Nadroparin)

Authors

P. Mismetti

¹From the Groupe de recherche sur la Thrombose, Saint-Etienne, France
S. Laporte-Simitsidis

¹From the Groupe de recherche sur la Thrombose, Saint-Etienne, France
C. Navarro

²Cinétique des xénobiotiques, Faculté de Pharmacie, Toulouse, France
P. Sié

²Cinétique des xénobiotiques, Faculté de Pharmacie, Toulouse, France
P. d’Azemar

³Sanofi Recherche, Gentilly, France
J. Necciari

³Sanofi Recherche, Gentilly, France
J. P. Duret

³Sanofi Recherche, Gentilly, France
C. Gaud

³Sanofi Recherche, Gentilly, France
H. Decousus

¹From the Groupe de recherche sur la Thrombose, Saint-Etienne, France
B. Boneu

⁴Laboratoire de Recherche sur l’Hémostase et la Thrombose, Toulouse, France

Abstract

Summary

Venous thromboembolism may be efficiently treated by one single daily administration of a high dose of low molecular weight heparin (LMWH). The present study investigates if the physiological deterioration of renal function associated with normal aging or the presence of an acute venous thromboembolism influences the pharmacodynamic pattern of the anti-factor Xa and anti-thrombin activities. Three groups of 12 subjects were investigated. The first 2 groups were composed of healthy volunteers differing by age (25 ± 4 and 65 ± 3 yrs) and creati-nine clearance (114 ± 15 and 62 ± 6 ml · min –1). The third group was composed of patients hospitalized for deep vein thrombosis, having a mean age of 65 ± 11 yrs and creatinine clearance of 76 ± 8 ml · min –1. Nadroparin was administered subcutaneously once daily at the dose of 180 anti-factor Xa IU.kg^–1 for 6 to 10 days. Serial sampling on day 1 and on the last day of administration (day n) allowed the pharmacodynamic parameters of the anti-factor Xa and anti-thrombin activities to be compared at the begining and at the end of the treatment. The main findings were the following: (1) After repeated administration, a significant accumulation of the anti-factor Xa activity was observed in the healthy elderly and in the patients but not in the healthy young subjects (accumulation factor: 1.3). There was no evidence of accumulation of anti-thrombin activity; (2) There were significant correlations between the clearance of creatinine and the clearance of the anti-factor Xa activity but not with that of the anti-thrombin activity; (3) In the patients, the clearance of the anti-factor Xa and of the anti-thrombin activities were 1.4 and 2 times higher respectively than those calculated in the healthy elderly; (4) The mean ratio of the of anti-factor Xa and anti-thrombin clearances was close to 2 in the healthy subjects but equal to 5.4 in the patients. These results suggest that the mechanisms involved in the clearance of polysaccharide chains which support the anti-thrombin activity are different from those of the anti-factor Xa activity and that the enhanced binding properties of plasma proteins to unfractionated heparin reported in patients presenting an acute venous thromboembolism also exists for LMWH, predominantly for the anti-thrombin activity.

Full Text

References

References
1 Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309: 299-304.
2 Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601-7.
3 Boneu B. Low molecular weight heparin therapy: Is monitoring needed?. Thromb Haemost 1994; 72: 330-4.
4 Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Bretell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenblomm D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
5 Holmström M, Berglund MC, Granquist S, Bratt G, Törnebohm E, Lockner D. Fragmin舘 once or twice daily subcutaneously in the treatment of deep vein thrombosis of the leg. Thromb Res 1992; 67: 49-55.
6 Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin^® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
7 Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Söderberg K. Once-daily subcutaneous Dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76: 195-9.
8 Charbonnier BA, Fiessinger JN, Sixma JJ, d’Azemar P, Sagnard L. Comparison of a once daily versus twice daily subcutaneous Nadroparin calcium regimens in the treatment of deep vein thrombosis. On behalf of the Fraxodi group. Circulation 1996; 94: 742 (abst).
9 Pioped investigators.. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the prospective investigation of pulmonary embolism diagnosis (Piomed). JAMA 1990; 263: 2753-9.
10 Briant L, Caranobe C, Saivin S, Sié P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY216: pharmacokinetics and bioavailabilities of the antifactor Xa and antithrombin effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-53.
11 Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
12 Boneu B, Caranobe C, Saivin S, Dol F, Sié P. Pharmacokinetics of heparin and of dermatan sulfate: clinical implications. In: Heparins and Related Polysaccharides. Lane DA, Björk I, Lindhal U. (eds) Plenum Press; New York: 1992. pp 237-47.
13 Peyrou P, Lormeau JC, Caranobe C, Gabaig AM, Crepon B, Saivin S, Houin G, Sie P, Boneu B. Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit. Thromb Haemost 1994; 72: 268-74.
14 Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-30.
15 Cosmi B, Fredenburgh J, Rischke J, Hirsh J, Young E, Weitz J. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 1997; 95: 118-24.
16 Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.